NPPA fixes retail prices for 14 formulations
The fixed formulations are used to treat diabetes, hypertension, cholesterol, women’s health and mental health disorders
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Dr Reddy’s Laboratories
Expect to launch 25 products in US this fiscal: Dr Reddy’s
As of March 31, 2020, the company has 99 cumulative filings pending for approval with the US Food and Drug Administration (US…
Dr Reddy’s Laboratories launch Abiraterone Acetate Tablets USP in the US
The drug is used for the treatment of prostate cancer
Centre clarifies reasons for delay in approvals for remdesivir
Informs that it is awaiting data on some crucial parameters from companies that have applied for manufacturing and marketing…
Dr Reddy’s signs licensing agreement with Gilead Sciences for remdesivir
Dr Reddy’s will receive technology transfer from Gilead for manufacturing of this drug and needs to do the manufacturing scale-up…
Dr Reddy’s announces launch of Colchicine Tablets USP in the US
It is available in 0.6 mg tablets in bottle count sizes of 30s and 100s
Dr Reddy’s Laboratories completes acquisition of Wockhardt’s select business divisions
The acquired divisions comprise a portfolio of 62 brands in multiple therapy areas such as respiratory, neurology, VMS,…
Dr Reddy’s PAT up 76 per cent in Q4, soft-launches HCQ in India
The performance was backed by tax deferment and growth in global generics, Dr Reddy's said
Dr Reddy’s recalls its heart burn medicine in the US
The move comes after US FDA found quality issues like ‘discolouration’ and presence of brown pellets in the company’s 40 mg…
Dr Reddy’s gets EIR from USFDA for Srikakulam plant
All facilities under warning letter are now determined as ‘voluntary action indicated’